Readystate Asset Management LP Invests $2.01 Million in NewAmsterdam Pharma (NASDAQ:NAMS)

Readystate Asset Management LP bought a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 121,000 shares of the company's stock, valued at approximately $2,009,000. Readystate Asset Management LP owned about 0.13% of NewAmsterdam Pharma as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of NAMS. abrdn plc raised its holdings in NewAmsterdam Pharma by 69.8% during the 3rd quarter. abrdn plc now owns 129,060 shares of the company's stock worth $2,142,000 after buying an additional 53,060 shares during the period. Millennium Management LLC increased its position in shares of NewAmsterdam Pharma by 23.0% in the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company's stock worth $22,388,000 after acquiring an additional 217,902 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of NewAmsterdam Pharma by 8.9% during the third quarter. Jennison Associates LLC now owns 1,020,278 shares of the company's stock valued at $16,937,000 after acquiring an additional 83,115 shares during the period. Lisanti Capital Growth LLC purchased a new stake in shares of NewAmsterdam Pharma in the 3rd quarter valued at approximately $700,000. Finally, GSA Capital Partners LLP boosted its stake in NewAmsterdam Pharma by 79.9% in the 3rd quarter. GSA Capital Partners LLP now owns 66,402 shares of the company's stock worth $1,102,000 after purchasing an additional 29,496 shares during the period. Institutional investors and hedge funds own 89.89% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Piper Sandler restated an "overweight" rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Needham & Company LLC reissued a "buy" rating and issued a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday. Finally, Royal Bank of Canada restated an "outperform" rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $33.80.

Insider Transactions at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 45,000 shares of the company's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the company's stock in a transaction on Friday, November 15th. The stock was sold at an average price of $25.02, for a total transaction of $213,420.60. Following the sale, the insider now directly owns 11,812,033 shares of the company's stock, valued at approximately $295,537,065.66. This represents a 0.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 86,803 shares of company stock worth $1,755,307 in the last 90 days. 19.50% of the stock is owned by insiders.

NewAmsterdam Pharma Stock Down 0.7 %

NewAmsterdam Pharma stock traded down $0.13 during trading hours on Thursday, hitting $18.14. The company had a trading volume of 594,039 shares, compared to its average volume of 302,119. The firm's fifty day moving average is $19.78 and its 200-day moving average is $18.56. NewAmsterdam Pharma has a fifty-two week low of $8.90 and a fifty-two week high of $26.35.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.